Abstract: A brachytherapy implant including a hollow biocompatible wire, and at least one tubular seed defining an internal channel. Radioactive particles for radiotherapy treatment are placed on the at least one tubular seed. The tubular seed is mounted externally on the hollow biocompatible wire. Possibly, the hollow biocompatible wire defines an internal channel having a diameter of less than 0.5 millimeters. Optionally, the hollow biocompatible wire is not biodegradable. The at least one tubular seed may be located in the middle of the hollow biocompatible wire, at least 10 millimeters from both ends of the hollow biocompatible wire.

Abstract: A casing holding one or more brachytherapy seeds for implanting in a patient, which in turn carry atoms of a radioactive element for radiotherapy treatment is filled with a viscous liquid in a manner preventing radiation from the one or more brachytherapy seeds from exiting the casing. The casing may include a metallic or non-metallic elongated tube configured for insertion into tissue or a vial for delivering a seed to a physician for insertion into a needle.

Abstract: A brachytherapy device including a base adapted for being at least partially introduced into a body of a subject and a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the base in a manner that not more than 15% of the radionuclide atoms leave the base in 24 hours, in methods other than radioactive decay. When installed in a human subject, the brachytherapy device emits radionuclide atoms of the first alpha-emitting isotope at a rate of at least 0.1% of the number of radionuclide atoms of the first alpha-emitting isotope coupled to the base, per 24 hours.

Abstract: A brachytherapy device (20, 21) including a base (22) adapted for being at least partially introduced into a body of a subject and a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the base in a manner that not more than 15% of the radionuclide atoms leave the base in 24 hours, in methods other than radioactive decay. When installed in a human subject, the brachytherapy device emits radionuclide atoms of the first alpha-emitting isotope at a rate of at least 0.1% of the number of radionuclide atoms of the first alpha-emitting isotope coupled to the base, per 24 hours.

Abstract: A casing holding one or more brachytherapy seeds for implanting in a patient, which in turn carry atoms of a radioactive element for radiotherapy treatment is filled with a viscous liquid in a manner preventing radiation from the one or more brachytherapy seeds from exiting the casing. The casing may include a metallic or non-metallic elongated tube configured for insertion into tissue or a vial for delivering a seed to a physician for insertion into a needle.